Literature DB >> 33545624

Antibodies to an Epstein Barr Virus protein that cross-react with dsDNA have pathogenic potential.

Divya Singh1, Omar Oudit2, Sabastian Hajtovic3, Dylan Sarbaugh4, Rafatu Salis4, Temitayo Adebowale4, Justin James3, Linda A Spatz5.   

Abstract

Pathogens such as the Epstein Barr virus (EBV) have long been implicated in the etiology of systemic lupus erythematosus (SLE). The Epstein Barr virus nuclear antigen I (EBNA-1) has been shown to play a role in the development of anti-nuclear antibodies characteristic of SLE. One mechanism by which EBV may play a role in SLE is molecular mimicry. We previously generated two monoclonal antibodies (mAbs) to EBNA-1 and demonstrated that they cross-react with double-stranded DNA (dsDNA). In the present study, we demonstrate that these mAbs have pathogenic potential. We show that they can bind to isolated rat glomeruli and that binding can be greatly diminished by pretreatment of glomeruli with DNase I, suggesting that these mAbs bind dsDNA in the kidney. We also demonstrate that these antibodies can deposit in the kidney when injected into mice and can induce proteinuria and elicit histopathological alterations consistent with glomerulonephritis. Finally, we show that these antibodies can cross-react with laminin and collagen IV in the extracellular matrix suggesting that direct binding to the glomerular basement membrane or mesangial matrix may also contribute to the antibody deposition in the kidney. In summary, our results indicate that EBNA-1 can elicit antibodies that cross-react with dsDNA, that can deposit in the kidney, and induce kidney damage. These results are significant because they support the role of a viral protein in SLE and lupus nephritis.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-dsDNA antibodies; Cross-reactivity; Epstein Barr Virus (EBV); Epstein Barr virus nuclear antigen 1 (EBNA-1); Molecular mimicry; Systemic lupus erythematosus (SLE)

Mesh:

Substances:

Year:  2021        PMID: 33545624     DOI: 10.1016/j.molimm.2021.01.013

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  3 in total

1.  Prevalence of anti-SARS-CoV-2 IgG antibodies in a group of patients, a control group, and healthcare workers of Thrace area in Greece, by the use of two distinct methods.

Authors:  Theocharis Konstantinidis; Stavroula Zisaki; Ioannis Mitroulis; Dimitrios Cassimos; Ioanna Nanousi; Eftychia G Kontekaki; Vasilis Petrakis; Kalliopi Parrisi; Eleni Fotiadou; Aikaterini Linardou; Nikolaos Lemonakis; Anastasia Grapsa; Theodora Gioka; Leonidas Lazidis; Charalampos Papagoras; Chistina Tsigalou; Periklis Panagopoulos; Panagiotis Skendros; Georges Martinis; Maria Panopoulou
Journal:  Germs       Date:  2021-09-29

2.  A High Prevalence of Anti-EBNA1 Heteroantibodies in Systemic Lupus Erythematosus (SLE) Supports Anti-EBNA1 as an Origin for SLE Autoantibodies.

Authors:  Viktoryia Laurynenka; Lili Ding; Kenneth M Kaufman; Judith A James; John B Harley
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 8.786

Review 3.  Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Can They Be Used as Biomarkers for the Differential Diagnosis of This Disease?

Authors:  Elias Manca
Journal:  Clin Rev Allergy Immunol       Date:  2021-06-11       Impact factor: 10.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.